Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsight The follicular lymphoma clinical trial analysis report delivers important insights into ...
Follicular dendritic cell sarcoma (FDCS) is an uncommon neoplasm originating from the accessory cells of the immune system that ordinarily play a crucial role in antigen presentation and the ...
At the recent American Society of Hematology (ASH) annual meeting, data from a phase I trial of AZD0486-- a novel CD19xCD3 bispecific T-cell engager -- showed high response rates and encouraging ...
Tsukuba, Japan—Follicular lymphoma is a common and recurrent form of malignant lymphoma. Although the role of T cells (a type of lymphocyte) in its development has been suggested, the diversity and ...
When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to treatment for some patients, with its high end durable response rates, and ...
Wednesday, the FDA granted accelerated approval to Bristol Myers Squibb Co’s (NYSE:BMY) Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, ...
Classical Hodgkin's Disease and Follicular Lymphoma Originating From the Same Germinal Center B Cell
Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+ B-Cell Non-Hodgkin's Lymphoma PURPOSE: Classical Hodgkin's disease and non-Hodgkin's B-cell lymphoma ...
Explore the promising role of Epcoritamab and bispecific therapies in second-line treatment for follicular lymphoma, enhancing patient outcomes. In the second-line management of follicular lymphoma, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results